Moleculin Biotech Book Value Per Share Growth & History (MBRX)
Moleculin Biotech's book value per share was $4.69 for fiscal 2025.
View full Moleculin Biotech company overviewMoleculin Biotech annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.69 | -$78.24 | −94.34% |
| 2024 | 2024-12-31 | $82.93 | -$264.19 | −76.11% |
| 2023 | 2023-12-31 | $347.11 | -$336.54 | −49.23% |
| 2022 | 2022-12-31 | $683.66 | -$352.88 | −34.04% |
| 2021 | 2021-12-31 | $1,036.53 | $459.25 | +79.55% |
| 2020 | 2020-12-31 | $577.29 | -$188.87 | −24.65% |
| 2019 | 2019-12-31 | $766.15 | -$359.45 | −31.93% |
| 2018 | 2018-12-31 | $1,125.60 | -$668.39 | −37.26% |
| 2017 | 2017-12-31 | $1,794.00 | -$972.99 | −35.16% |
| 2016 | 2016-12-31 | $2,766.99 | — | — |
Moleculin Biotech quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.63 | $4.60 | — |
| Q1 2026 | 2026-03-31 | $2.85 | -$21.56 | −88.34% |
| Q4 2025 | 2025-12-31 | $4.69 | -$78.24 | −94.34% |
| Q3 2025 | 2025-09-30 | -$13.60 | -$158.60 | — |
| Q2 2025 | 2025-06-30 | -$2.97 | -$192.45 | — |
| Q1 2025 | 2025-03-31 | $24.40 | -$209.07 | −89.55% |
| Q4 2024 | 2024-12-31 | $82.93 | -$264.19 | −76.11% |
| Q3 2024 | 2024-09-30 | $145.00 | -$297.02 | −67.20% |
| Q2 2024 | 2024-06-30 | $189.48 | -$317.43 | −62.62% |
| Q1 2024 | 2024-03-31 | $233.47 | -$345.29 | −59.66% |
| Q4 2023 | 2023-12-31 | $347.11 | -$336.54 | −49.23% |
| Q3 2023 | 2023-09-30 | $442.02 | -$323.19 | −42.24% |
| Q2 2023 | 2023-06-30 | $506.91 | -$362.98 | −41.73% |
| Q1 2023 | 2023-03-31 | $578.76 | -$374.74 | −39.30% |
| Q4 2022 | 2022-12-31 | $683.66 | -$352.88 | −34.04% |
| Q3 2022 | 2022-09-30 | $765.21 | -$301.10 | −28.24% |
| Q2 2022 | 2022-06-30 | $869.89 | -$242.55 | −21.80% |
| Q1 2022 | 2022-03-31 | $953.50 | -$213.46 | −18.29% |
| Q4 2021 | 2021-12-31 | $1,036.53 | $459.25 | +79.55% |
| Q3 2021 | 2021-09-30 | $1,066.31 | $539.30 | +102.33% |
| Q2 2021 | 2021-06-30 | $1,112.44 | $530.26 | +91.08% |
| Q1 2021 | 2021-03-31 | $1,166.96 | $520.55 | +80.53% |
| Q4 2020 | 2020-12-31 | $577.29 | -$188.87 | −24.65% |
| Q3 2020 | 2020-09-30 | $527.02 | -$406.64 | −43.55% |
| Q2 2020 | 2020-06-30 | $582.18 | -$517.61 | −47.06% |
| Q1 2020 | 2020-03-31 | $646.41 | -$313.64 | −32.67% |
| Q4 2019 | 2019-12-31 | $766.15 | -$359.45 | −31.93% |
| Q3 2019 | 2019-09-30 | $933.65 | -$320.20 | −25.54% |
| Q2 2019 | 2019-06-30 | $1,099.78 | -$303.08 | −21.60% |
| Q1 2019 | 2019-03-31 | $960.05 | -$836.01 | −46.55% |
| Q4 2018 | 2018-12-31 | $1,125.60 | -$668.39 | −37.26% |
| Q3 2018 | 2018-09-30 | $1,253.85 | -$761.54 | −37.79% |
| Q2 2018 | 2018-06-30 | $1,402.86 | -$747.18 | −34.75% |
| Q1 2018 | 2018-03-31 | $1,796.06 | -$249.32 | −12.19% |
| Q4 2017 | 2017-12-31 | $1,794.00 | -$972.99 | −35.16% |
| Q3 2017 | 2017-09-30 | $2,015.38 | -$1,016.45 | −33.53% |
| Q2 2017 | 2017-06-30 | $2,150.04 | -$1,345.99 | −38.50% |
| Q1 2017 | 2017-03-31 | $2,045.38 | $2,273.48 | — |
| Q4 2016 | 2016-12-31 | $2,766.99 | $3,018.54 | — |
| Q3 2016 | 2016-09-30 | $3,031.83 | — | — |
| Q2 2016 | 2016-06-30 | $3,496.03 | — | — |
| Q1 2016 | 2016-03-31 | -$228.10 | — | — |
| As of Dec 31, 2015 | 2015-12-31 | -$251.55 | — | — |
Moleculin Biotech book value per share trends
Over the last five fiscal years, Moleculin Biotech's book value per share decreased from $577.29 to $4.69, a change of -$572.60. The latest reported quarter, Q2 2026, shows $1.63.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Moleculin Biotech source filings ↗